Sunshine Biopharma (SBFM) Capital Expenditures (QoQ) (2017 - 2026)
Sunshine Biopharma (SBFM) Capital Expenditures (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Sunshine Biopharma | 1.60 Mn | -12.15 Mn | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.77% |
| Mar 31, 2026 | 593.65% |
| Dec 31, 2025 | -112.92% |
| Sep 30, 2025 | -94.98% |
| Jun 30, 2025 | 2,036.18% |
| Mar 31, 2025 | -92.70% |
| Dec 31, 2024 | -80.15% |
| Sep 30, 2024 | -46.95% |
| Jun 30, 2024 | 1,448.39% |
| Mar 31, 2024 | 116.46% |
| Dec 31, 2023 | -4,068.89% |
| Dec 31, 2020 | -51.13% |
| Dec 31, 2019 | 277.32% |
| Sep 30, 2019 | -200.00% |
| Dec 31, 2018 | -270.40% |
| Sep 30, 2018 | -71.57% |
| Jun 30, 2018 | 267.70% |
| Mar 31, 2018 | 28.64% |
| Dec 31, 2017 | 116.68% |
| Sep 30, 2017 | -200.00% |